Number of items: 15.
2024
Boey, A., Bryce, A. , Dickson, E., Coats, M., McKay, C., Jamieson, N. , Chang, D. , Holroyd, D. and Dreyer, S.
(2024)
The Impact of Pre-operative Indeterminate Lung Nodules in the Surgical Management of Pancreatic Ductal Adenocarcinoma.
16th World Congress of the International Hepato-Pancreato-Biliary Association, Cape Town, South Africa, 15-18 May 2024.
S148.
(doi: 10.1016/j.hpb.2024.03.269)
2023
Dreyer, S. B. et al.
(2023)
The impact of molecular subtyping on pathological staging of pancreatic cancer.
Annals of Surgery, 277(2),
e396-e405.
(doi: 10.1097/SLA.0000000000005050)
(PMID:36745763)
(PMCID:PMC9831035)
2022
Ali, A. et al.
(2022)
Prognostic implications of microRNA-21 overexpression in pancreatic ductal adenocarcinoma: an international multicenter study of 686 patients.
American Journal of Cancer Research, 12(12),
pp. 5668-5683.
(PMID:36628279)
(PMCID:PMC9827095)
2021
Dreyer, S. B. et al.
(2021)
Targeting DNA damage response and replication stress in pancreatic cancer.
Gastroenterology, 160(1),
pp. 362-377.
(doi: 10.1053/j.gastro.2020.09.043)
(PMID:33039466)
(PMCID:PMC8167930)
2020
Dreyer, S. B. et al.
(2020)
Precision oncology in surgery: patient selection for operable pancreatic cancer.
Annals of Surgery, 272(2),
pp. 366-376.
(doi: 10.1097/SLA.0000000000003143)
(PMID:32675551)
(PMCID:PMC7373491)
Brunton, H. et al.
(2020)
HNF4A and GATA6 loss reveals therapeutically actionable subtypes in pancreatic cancer.
Cell Reports, 31(6),
107625.
(doi: 10.1016/j.celrep.2020.107625)
(PMID:32402285)
Dreyer, S.B., Jamieson, N.B. , Cooke, S.L. , Valle, J.W., McKay, C.J., Biankin, A.V. and Chang, D.K.
(2020)
PRECISION-Panc: the next generation therapeutic development platform for pancreatic cancer.
Clinical Oncology, 32(1),
pp. 1-4.
(doi: 10.1016/j.clon.2019.07.011)
(PMID:31378449)
2019
Janssen, Q. P. et al.
(2019)
Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis.
Journal of the National Cancer Institute, 111(8),
pp. 782-794.
(doi: 10.1093/jnci/djz073)
(PMID:31086963)
(PMCID:PMC6695305)
Dreyer, S. B. et al.
(2019)
Feasibility and clinical utility of endoscopic ultrasound guided biopsy of pancreatic cancer for next-generation molecular profiling.
Chinese Clinical Oncology, 8(2),
16.
(doi: 10.21037/cco.2019.04.06)
(PMID:31070037)
2018
Dreyer, S.B., Jamieson, N.B. , Upstill-Goddard, R., Bailey, P.J. , McKay, C.J., Australian Pancreatic Cancer Genome Initiative, , Biankin, A.V. and Chang, D.K.
(2018)
Defining the molecular pathology of pancreatic body and tail adenocarcinom.
British Journal of Surgery, 105(2),
e183-e191.
(doi: 10.1002/bjs.10772)
(PMID:29341146)
(PMCID:PMC5817249)
2017
Grose, D. et al.
(2017)
The role of induction chemotherapy + chemoradiotherapy in localised pancreatic cancer: initial experience in Scotland.
Journal of Gastrointestinal Oncology, 8(4),
pp. 683-695.
(doi: 10.21037/jgo.2017.04.01)
(PMID:28890819)
(PMCID:PMC5582039)
Humphris, J. L. et al.
(2017)
Hypermutation in pancreatic cancer.
Gastroenterology, 152(1),
68-74.e2.
(doi: 10.1053/j.gastro.2016.09.060)
(PMID:27856273)
2016
Jabbar, S.A.A., Jamieson, N.B. , Morris, A.J., Oien, K.A. , Duthie, F., McKay, C.J., Carter, C.R. and Dickson, E.J.
(2016)
A Glasgow tipple-transjugular intrahepatic portosystemic shunt insertion prior to Whipple resection.
Journal of Surgical Case Reports, 2016(5),
rjw089.
(doi: 10.1093/jscr/rjw089)
(PMID:27177892)
(PMCID:PMC4866079)
Ali, A. et al.
(2016)
Investigating various thresholds as immunohistochemistry cutoffs for observer agreement.
Applied Immunohistochemistry and Molecular Morphology, 25(9),
pp. 599-608.
(doi: 10.1097/PAI.0000000000000357)
(PMID:27093449)
2013
Chang, D. K. , Jamieson, N. B. , Scarpa, A., McKay, C. J. and Biankin, A. V.
(2013)
Reply to G.F. Arroyo.
Journal of Clinical Oncology, 31(30),
pp. 3843-3844.
(doi: 10.1200/JCO.2013.51.3176)
(PMID:24043730)
This list was generated on Tue Sep 17 09:25:46 2024 BST.
